Credible Studies Show Elmiron PPS Does Not Alleviate Bladder Pain And Claims That It Does Are False

Taking a full dose of Elmiron showed no greater pain relief than taking a placebo or taking one-third of the recommended dose

Thursday, October 28, 2021 - Interstitial cystitis (IC) is a condition that affects women who have recently given birth and sometimes men. Women with IC report having to urinate up to 60 times per day in small amounts with the urgency of emergency urination. Women with IC are constantly worried about having a urinary accident and must be prepared to run to the toilet wherever they are. Women with IC also experience chronic pain in the pelvis or between the vagina and anus. Hundreds of women and some men have filed Elmiron eye lawsuits seeking compensation for their vision injuries. The MayoClinic describes IC as constant bladder pressure and pain. Urologists have been recommending that women with IC take Elmiron (pentosan polysulfate sodium). Elmiron is made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The company has enjoyed a monopoly since its FDA approval in 1996. Johnson & Johnson has made billions of dollars selling Elmiron, but studies indicate that it works no better than a placebo at relieving bladder pain or lessening the urge to urinate. Elmiron takes at least three months to build up in the blood to alleviate bladder pain. Doctors insist that an IC patient take no more than the prescribed dosages of Elmiron.

It has recently come out that Elmiron may be responsible for causing a type of eyesight damage called pigmentary maculopathy. Studies indicate that up to 25% of women that have taken the drug may develop permanent, Elmiron vision loss and that discontinuing Elmiron will not stop the condition from progressing. Other Elmiron side effects are those of the thinning of the blood such as brushing more easily, more frequent nosebleeds, bleeding in the gums, and blood in the stool, according to the warnings now on the company website. Janssen failed to warn consumers of Elmiron of what they knew or were expected to know about the vision damaging side effects of the drug.

Millberg law firm (MLF) writes on their website that the companies making Elmiron knew for years about Elmiron vision damage but failed to warn customers or the FDA. "These cases were first documented in 2018, but Elmiron has been prescribed for decades without any warning about eye damage. The labeling was updated in 2020 to reflect the risk of pigmentary maculopathy from long-term use of Elmiron," MLF wrote. It is also interesting to note that the reason no competition has ever arisen for Elmiron is that it may have never worked in the first place, and patients are merely experiencing the placebo effect. The Journal of Urology reported that the claims of Elmiron helping patients with IC were false. JU wrote: "Results of this study in a broad population of patients with symptoms consistent with interstitial cystitis revealed no treatment effect vs. placebo for pentosan polysulfate sodium at the currently established dose or a third of the daily dose. There was no statistically significant difference between the pentosan polysulfate sodium group and the placebo group."

More Recent Elmiron Eye Lawsuit News:

Lawyers for Elmiron Eye Lawsuits

Attorneys handling Elmiron Eye lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Elmiron Eye lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Elmiron Eye lawsuit. The product liability litigators handling Roundup claims at OnderLaw have a strong track record of success in representing families harmed by dangerous drugs and consumer products.